Tvardi Therapeutics Files 8-K

Ticker: TVRD · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1346830

Tvardi Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyTvardi Therapeutics, Inc. (TVRD)
Form Type8-K
Filed DateNov 19, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-disclosure, financials

TL;DR

Tvardi Therapeutics filed an 8-K on Nov 19, 2025, covering Reg FD and financials.

AI Summary

Tvardi Therapeutics, Inc. filed an 8-K on November 19, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Cara Therapeutics, Inc., is incorporated in Delaware and headquartered in Sugar Land, Texas.

Why It Matters

This filing provides updates on Tvardi Therapeutics' regulatory disclosures and financial exhibits, which are important for investors to understand the company's current status and compliance.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.

Key Players & Entities

  • Tvardi Therapeutics, Inc. (company) — Registrant
  • Cara Therapeutics, Inc. (company) — Former company name
  • November 19, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Sugar Land, Texas (location) — Principal executive address

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves to report on Regulation FD Disclosure and Financial Statements and Exhibits for Tvardi Therapeutics, Inc.

When was this report filed?

The report was filed on November 19, 2025.

What was Tvardi Therapeutics, Inc. formerly known as?

Tvardi Therapeutics, Inc. was formerly known as Cara Therapeutics, Inc.

In which state is Tvardi Therapeutics, Inc. incorporated?

Tvardi Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive address of Tvardi Therapeutics, Inc.?

The principal executive address is 3 Sugar Creek Ctr. Blvd. Suite 525, Sugar Land, Texas 77478.

Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-19 06:44:08

Key Financial Figures

  • $0.001 — registered Common Stock, par value $0.001 per share TVRD The Nasdaq Stock Marke

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 19, 2025, Tvardi Therapeutics, Inc. (the "Company") made available an updated corporate presentation, which can be found on the Company's website (the "Corporate Presentation"). The Corporate Presentation is furnished as Exhibit 99.1 and is incorporated herein by reference. The information contained herein and the accompanying Exhibit 99.1 is being furnished under "Item 7.01 Regulation FD Disclosure" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated November 19, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TVARDI THERAPEUTICS, INC. Date: November 19, 2025 By: /s/ Imran Alibhai Name: Imran Alibhai Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.